
## **Supplementary Information**

## **Evaluation of a PSMA-Targeted BNF Nanoparticle Construct**


Babak Behnam Azad,<sup>1</sup> Sangeeta R. Banerjee,<sup>1</sup> Mrudula Pullambhatla,<sup>1</sup> Silvia Lacerda,<sup>2</sup>

Catherine A. Foss,<sup>1</sup> Yuchuan Wang,<sup>1</sup> Robert Ivkov,<sup>3</sup> Martin G. Pomper<sup>1,3</sup>

<sup>1</sup>Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA; <sup>2</sup>Centre for Biological Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA; <sup>3</sup>Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medical Institutions, Baltimore, MD, USA



**Figure 1S.** NanoSight characterization of non-modified () and modified () BNFs showing particle diameters (left column) and the corresponding light scattering patterns (right column)



**Figure 2S.** Representative *in vivo* optical images of mice (ventral view) bearing PC3 PSMA+ (PIP; blue arrow) and PSMA- (flu; white arrow) tumors over 24 h, depicting the effect of over (a) and under PEGylation of BNF particles.